We have recapped some of the top news presented from the conference—and soon we’ll speak with Dr S. Vincent Rajkumar on the most exciting multiple myeloma studies, and Dr Sara Tolaney on the pivotal breast cancer abstracts.

Welcome to OncLive News Network! I’m Gina Columbus.

In the phase III SOPHIA study, the combination of the HER2-targeted therapy margetuximab with chemotherapy improved progression-free survival compared with trastuzumab and chemotherapy in pretreated patients with HER2-positive metastatic breast cancer. Currently, overall survival data are maturing.

Moreover, CD16A genotyping suggested a differential benefit in patients with a 158F allele. Also in HER2-positive breast cancer, neratinib plus capecitabine led to a significant improvement in progression-free survival compared with lapatinib and capecitabine in patients with HER2-positive metastatic breast cancer who were previously treated with at least 2 HER2-directed regimens.

Additionally, there was a trend towards improved overall survival in the neratinib arm as well as delayed time to intervention for symptomatic central nervous system disease. In terms of tolerability, the 2 arms were similar. In chronic lymphocytic leukemia, three-year follow-up showed that acalabrutinib combined with obinutuzumab was associated with high, durable, and deep response rates in patients with both treatment-naïve and relapsed/refractory disease.

In the phase Ib/II trial, 19 treatment-naïve patients and 26 relapsed/refractory patients were treated, and the median age overall was 61 years.

A five-year analysis of the long-term effects of the frontline combination of dabrafenib and trametinib in patients with BRAF V600—mutant unresectable or metastatic melanoma showed that the regimen continues to have durable long-term benefit.

Regarding tolerability, no new safety signals were observed with the combination, and there were no treatment-related deaths.

In EGFR-mutant non—small cell lung cancer, results of the RELAY trial showed that the frontline combination of ramucirumab plus erlotinib improved progression-free survival compared with ramucirumab and placebo in EGFR-mutant metastatic NSCLC.

Moreover, the safety findings were consistent with the established tolerability profiles of each agent alone. Also in melanoma, updated results of the CheckMate-204 trial showed that first-line nivolumab combined with ipilimumab led to a high rate of durable intracranial responses in patients with symptomatic melanoma brain metastases.

However, longer follow-up is needed in an effort to understand mechanisms of resistance to PD-1/CTLA-4 inhibition.

For a full review of all of these studies, please visit OncLive.com.

That’s all for today.

And don’t forget! The OncLive Global Expo is taking place October 11th through 13th in Orlando, Florida. Join us for a fully interactive meeting that brings together the most inclusive group of oncology professionals to collaborate on emerging trends and technologies in oncology care and research.

Thank you for watching OncLive News Network: On Location. Signing off from the 2019 ASCO Annual Meeting! I’m Gina Columbus.